The Global Low Molecular Weight Heparin
Market, by Drug (Enoxaparin, Dalteparin, Nadroparin, Bemiparin, Tinzaparin, and Others), by Packaging (Multi-vials and Prefilled Syringes), by Application (Deep Vein Thrombosis, Acute Coronary Syndrome (ACS), Pulmonary Embolism and Atrial Fibrillation), by End Use (Hospitals (Private and Public), Clinics, and Home) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued US$ 3,050.4 million in 2018, and is projected to exhibit a CAGR of 6.7% during the forecast period (2018 - 2026) as highlighted in a new report published by Coherent Market Insights.
Low molecular weight heparin
in the treatment of severe acute pancreatitis: a multiple centre prospective clinical study.
The impact of different methods of subcutaneous low molecular weight heparin
on the patients' pain.
Di, "Low molecular weight heparin
and cancer survival: clinical trials and experimental mechanisms," Journal of Cancer Research and Clinical Oncology, vol.
Gent et al., "An open-label randomized controlled trial of low molecular weight heparin
compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial," Thrombosis Research, vol.
Caption: Figure 1: Effects of low molecular weight heparin
nebulization on partial pressure arterial oxygen (Pa[O.sub.2]).
A low molecular weight heparin
inhibits experimental metastasis in mice independently of the endothelial glycocalyx.
The study concluded that the addition of 250 g/ml of 5 fluorouracil and 1 lU/ml of low molecular weight heparin
to the infusion fluid during vireous surgery do not significantly improve the success rates to retinal re-attachment.
The current options for therapeutic anticoagulation are unfractionated heparin (UFH), warfarin and low molecular weight heparin
Heparin-induced thrombocytopenia is a rare but potentially fatal complication of low molecular weight heparin
Ten percent of those who received low molecular weight heparin
suffered symptomatic bleeding in their brains, and 5% of those who received usual heparin developed severe non-brain bleeding; all had been given their heparin in the acute phase after their stroke, followed by warfarin.
Cohen, et al, the researchers determined that in only 40 percent of medical patients who were at risk for VTE and only 60 percent of surgical patients at risk for VTE received prophylactic treatment with Heparin or a low molecular weight Heparin